Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Total Current Liabilities
All obligations due within one year.
Sagimet Biosciences Inc.NASDAQ: SGMT
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 26.2% from a year ago
Total current liabilities stood at $5.3M at the end of Q1 FY2026, down 26.2% from a year earlier and up 3.8% from the prior quarter. Over 3 fiscal years it compounded at -1.1% a year.
Context
- Total current liabilities amounted to 4.9% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -26.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 5.1M USD
- Year-over-year change
- +14.5%
- 4-year CAGR
- +20.2%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.1M | +14.5% |
| FY2024 | 2024-12-31 | 4.45M | -21.2% |
| FY2023 | 2023-12-31 | 5.65M | +7.1% |
| FY2022 | 2022-12-31 | 5.28M | +116.4% |
| FY2021 | 2021-12-31 | 2.44M | — |
Total Current Liabilities vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's Mar 2026 total current liabilities of $5.3M is the lowest of the 11 companies compared; the peer median is $26.28M.
- Its year-over-year change of -26.2% is the 8th highest of 11, against a peer median of -14.4%.
- Total current liabilities amounts to 4.9% of total assets for SGMT, versus a peer median of 13.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $4.97B | +97278.1% | +7.7% | 2.3% | |
| Mar 2026 | $64.4M | -9.7% | +2.7% | 29.0% | |
| Mar 2026 | $35M | -24.9% | +44.1% | 14.9% | |
| Mar 2026 | $34.37M | -30.4% | -34.1% | 14.0% | |
| Mar 2026 | $33.37M | +53.4% | +29.1% | 12.5% | |
| Mar 2026 | $19.2M | +4.1% | +3.6% | 5.7% | |
| Mar 2026 | $17.45M | -56.6% | -28.5% | 8.0% | |
| Mar 2026 | $16.19M | -19.2% | -2.1% | 14.6% | |
| Mar 2026 | $11.83M | +66.0% | -25.1% | 35.7% | |
ZURAZura Bio Limited | Mar 2026 | $11.75M | -44.3% | -5.7% | 5.1% |
SGMTSagimet Biosciences Inc. | Mar 2026 | $5.3M | -26.2% | -1.1% | 4.9% |
| Peer median (excluding SGMT) | $26.28M | -14.4% | +0.3% | 13.2% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.